Bayer partners with Acuitas for LNP delivery technology
Together with its gene therapy unit AskBio, Bayer will access Acuitas’ high-potency ionisable lipid technology and LNP carriers,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Jun 23
Together with its gene therapy unit AskBio, Bayer will access Acuitas’ high-potency ionisable lipid technology and LNP carriers,…
02 Jun 23
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
30 May 23
Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024…
24 May 23
The partnership is aimed at creating groundbreaking therapies for rare genetic disorders, as well as widely prevalent cardiometabolic…
17 May 23
Astellas and Sony will jointly develop and optimise a new ADC platform using KIRAVIA Backbone as a linker,…
17 May 23
The partnership will combine Scribe Therapeutics’ CRISPR by Design approach with Prevail Therapeutics’ expertise in genetic medicines development…
16 May 23
Arcus will receive an upfront payment of $35m and will commence research programs against up to four targets,…
15 May 23
Rona Therapeutics will use its RAZOR platform to discover and identify siRNA lead compounds directed to a novel…
08 May 23
The biotechnology company has entered negotiations with a major global pharmaceutical company, for the development and commercialisation of…
03 May 23
Janssen will obtain an exclusive license to develop and commercialise CBMG’s C-CAR039 and C-CAR066 in geographic territories outside…